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Abstract
HIV-infected individuals are at increased risk for cardiovascular disease (CVD) and
lipodystrophy, but the relationship between regional adipose tissue (AT) depots and CVD risk is
not well-described. We determined regional AT volumes and CVD risk in an analysis of 586 HIV-
infected and 280 control FRAM study subjects using whole-body magnetic resonance imaging
(MRI) and the Framingham Risk Score (FRS). Median FRS and FRS >10% were higher in HIV
than control men (4.7% vs. 3.7%, p=0.0002; 16% vs. 4%, p<0.0001). HIV and control women had
similarly-low FRS (1.1% vs. 1.2%, p=0.91). In controls, total AT and all regional AT depots
showed strong positive correlations with FRS (p<0.001) in men, and weaker positive correlations
in women. Greater visceral AT (VAT) and lower leg subcutaneous AT (SAT) volumes were
associated with elevated FRS in HIV subjects, with a trend for upper trunk SAT. Controls in the
lowest quartile of leg SAT had the lowest FRS (1.5%), whereas HIV with similarly-low leg SAT
had the highest FRS (4.0%, p<0.001 vs. controls). Increased VAT is associated with CVD risk, but
the risk is higher in HIV-infected individuals relative to controls at every level of VAT. Peripheral
lipoatrophy (as measured by leg SAT) is associated with striking increased CVD risk in HIV-
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infected patients, even after controlling for VAT, whereas low leg SAT is associated with low
CVD risk in controls.
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Introduction
HIV-infected patients are at increased risk of cardiovascular disease (CVD), a finding
independently linked to both HIV infection and antiretroviral therapy (ART) (J. S. Currier et
al., 2003; De Socio et al., 2008; Dolan et al., 2005; Friis-Moller et al., 2003; Hadigan et al.,
2003; Kotler, 2008; Lee et al., 2004; Stein et al., 2001; Triant, Lee, Hadigan, & Grinspoon,
2007). Metabolic disturbances such as insulin resistance, pro-atherogenic lipid profiles, and
changes in subcutaneous and visceral fat distribution are common in HIV-infected patients
both on and off ART, and may contribute to this increased risk of CVD (Bacchetti et al.,
2005; J. Currier et al., 2008; De Socio et al., 2008; Dolan et al., 2005; El-Sadr et al., 2005;
Fat distribution in women with HIV infection,” 2006; Grunfeld et al., 1989; Grunfeld et al.,
1992; Grunfeld et al., 2007; Hadigan et al., 2003; Lee et al., 2004; Mulligan et al., 2006;
Nieves et al., 2003; Snijder et al., 2005; Stein et al., 2001; Tien et al., 2003; Wohl et al.,
2008). Sex differences in lipid abnormalities and preferential sites of fat distribution have
been reported (Bacchetti et al., 2005; J. Currier et al., 2008; Fat distribution in women with
HIV infection,” 2006; Galli et al., 2003; Wohl et al., 2008), but the specific contribution of
regional adipose tissue (AT) deposition to CVD risk in HIV infection has not been defined.
We previously demonstrated differences in lipid profiles, insulin resistance, and regional fat
depots between HIV-infected and control men and women in the Study of Fat Redistribution
and Metabolic Change in HIV Infection (FRAM) (Bacchetti et al., 2005; J. Currier et al.,
2008; Fat distribution in women with HIV infection,” 2006; Grunfeld et al., 2007; Wohl et
al., 2008). HIV infection was associated with insulin resistance, increased triglycerides, and
decreased low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol in
both sexes. In both HIV-infected and control subjects, greater visceral adipose tissue (VAT)
and upper trunk subcutaneous adipose tissue (SAT) were associated with insulin resistance.
Greater VAT was associated with lower HDL in HIV-infected subjects and controls, and
greater upper trunk SAT was associated with lower HDL in control men.
The associations between AT depots and triglyceride levels were more complex. Greater
VAT was associated with higher triglycerides in most groups. Among controls, greater
upper trunk SAT in women and greater lower trunk SAT in men were also associated with
higher triglycerides. In contrast, greater leg SAT was associated with lower triglycerides in
most groups. Together, these findings suggest that the increased risk of CVD seen in HIV
infection may partially be mediated by changes in regional fat deposition, and that the
contribution of individual CVD risk factors to overall risk may vary between men and
women.
The aim of this analysis was to determine the association between regional AT distribution
and 10-year Framingham Risk Scores (FRS) among HIV-infected and control men and
women in the FRAM study. While previous studies have used FRS to examine the CVD risk
profile in HIV-infected cohorts (Aboud et al.; Friis-Moller et al.; Rossi et al., 2009), no
nationally representative study has examined the association of magnetic resonance imaging
(MRI)-quantified regional adipose tissue with CVD risk.
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The FRAM study analyzed 1,480 HIV-infected men and women representative of patients in
care in the US between 2000-2004. It was the first large scale, objective, and quantitative
analysis (via MRI) of total body, regional subcutaneous, and visceral adipose tissue
abnormalities and their relationships to metabolic disturbances in HIV-infected patients.
Controls for the FRAM study are comprised of subjects from the Visceral Fat and Metabolic
Rate in Young Adults (VIM) sub-study of the Coronary Artery Risk Development in Young
Adults (CARDIA) study of CVD risk in the general population.
Details regarding FRAM participant and control selection, sample characteristics, and data
analysis tools have previously been published (Tien et al., 2006). In summary, our
population represents 1,183 HIV-infected persons and 297 controls from the first FRAM
examination. HIV-infected subjects were recruited from June 2000-September 2002 from 16
geographically diverse HIV/Infectious Disease clinics or cohorts, and are believed to
provide a representative cross-section of HIV-infected patients in care at that time (Tien et
al., 2006). Control men and women were participants in the Visceral Fat and Metabolic Rate
in Young Adults (VIM) sub-study of the population-based CARDIA study (Friedman et al.,
1988). All controls were consented for participation in the FRAM study during routine
CARDIA follow-up visits in 2000. Subjects were excluded if they had known
contraindications to MRI scanning or were: unable or unwilling to provide informed
consent, less than 18 years of age, pregnant, or planning to become pregnant in the
subsequent three months. Informed consent was obtained from all participants in accordance
with guidelines for human experimentation of the U.S. Department of Health and Human
Services and the institutional review board of each participating institution.
Participants in both studies underwent: whole-body MRI for regional fat volume analysis
(Gallagher et al., 1998); cholesterol subsets including fasting (>eight hours) direct LDL,
HDL, and triglycerides; and fasting blood glucose. Blood specimens were analyzed in a
single, centralized laboratory (Covance, Indianapolis, Indiana). For the purpose of
comparison, the age of HIV-infected subjects was restricted to 33–45 years old to match the
age range of controls. 586 HIV-infected FRAM subjects (408 male, 178 female) met this
criterion and were included in the age-restricted analyses. AT volumes were normalized in
all analyses by dividing by height squared, with summaries back-transformed to 1.75 m of
height.
Ten-year CVD risk was estimated by the Framingham Risk Equation using the Anderson
method (Anderson, Wilson, Odell, & Kannel, 1991), which was developed to accurately
estimate risk for persons 30-74 years of age. These sex-specific risk calculations are based
on age, total and HDL cholesterol levels, diastolic blood pressure, presence of diabetes,
smoking status, and presence of left ventricular hypertrophy on electrocardiography (set to
zero in this analysis as data unavailable). The equation estimates the 10-year risk for CVD
events including angina pectoris, coronary insufficiency, myocardial infarction (including
silent and unrecognized myocardial infarction), and death from coronary heart disease
(sudden or non-sudden). In sensitivity analyses, we also evaluated an alternative version of
the Framingham risk equation using systolic instead of diastolic blood pressure; the two
versions were found to be highly correlated in this population (r=0.98), and results were
similar. Sufficient data was available to calculate FRS for all 586 HIV-infected subjects and
280 control subjects. AT volumes were available for 519 HIV-infected and 260 control
subjects; demographic and clinical characteristics were similar in those with and without
MRI data.
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Characteristics of HIV-infected participants and controls were compared and tested for
statistical significance using the Mann-Whitney U test for continuous variables and Fisher’s
exact test for categorical variables. Spearman rank correlation coefficients were calculated
to assess associations between AT depots and FRS. Associations of AT depots with FRS
were compared between HIV and control subjects using tests of interaction. AT depots were
quartiled using cut-offs from the control group (performed separately by sex) to facilitate
comparison of similar quantities of AT. We did not adjust for body mass index (BMI), as
BMI is influenced by fat volume, the phenomenon being studied.
We examined the association of quartiled VAT and leg SAT with FRS in separate linear
regression models for HIV-infected and control participants. Because of its skewed
distribution, FRS was log-transformed; results were back-transformed to produce estimated
percentage differences in FRS attributable to each AT depot. Additionally, we tested the
interaction of HIV status with each AT depot in a single model that combined HIV-infected
and control participants.
All analyses were conducted using the SAS system, version 9.2 (SAS Institute, Inc., Cary,
NC).
Results
A sex-stratified comparison of demographic and clinical characteristics between HIV-
infected and control groups is presented in Table 1. A detailed characterization of FRAM
participants has previously been described (Tien et al., 2006). Among the HIV-infected
subjects analyzed, median age was 40 years (IQR 37-43) for men and 39 years (IQR 36-42)
for women. HIV-infected men were predominantly Caucasian (57%), whereas HIV-infected
women were more likely to be African-American (55%). In keeping with the design of the
CARDIA study, there were similar numbers of Caucasian and African-American subjects
among controls.
As previously reported, smoking was statistically significantly more common in HIV-
infected participants than controls (p<0.001 for men and women) (J. Currier et al., 2008;
Wohl et al., 2008). The overall prevalence of diabetes (defined as fasting glucose ≥126 mg/
dL or current use of hypoglycemic agents) was low (HIV vs. control men: 5% vs. 2%,
p=0.15; women: 9% vs. 5%, p=0.18).
HIV-infected men had lower total SAT, regional SAT, and VAT volumes compared with
controls (Table 1). In HIV-infected women, total SAT volume and most SAT depots were
smaller than in controls. An exception was upper trunk SAT, which was not lower in HIV-
infected compared with control women (5.9 L vs. 5.2 L, p=0.21). VAT was also not lower in
HIV-infected compared with control women (1.3 L vs. 1.1 L, p=0.055).
Framingham risk score in HIV-infected participants vs. controls
Levels of CVD risk by FRS (Table 2) were higher in HIV-infected men compared with
control men (median 4.7% vs. 3.7%, p=0.0002), but were similar in HIV-infected and
control women (1.1% vs. 1.2%, p=0.91). The prevalence of 10-year CVD risk >10% was
also higher in HIV-infected men than control men (16% vs. 4%, p<0.0001), but was again
similarly-low in HIV-infected and control women (3% vs. 1%, p=0.25). The prevalence of
10-year CVD risk >20% was 2% in HIV-infected men vs. 0% in control men (p=0.12).
None of the women had 10-year CVD risk >20%, regardless of HIV status.
Pre-existing CVD was self-reported by 4% of both HIV-infected men and women at study
entry compared with 6% pre-existing CVD in control participants. Although CVD was an
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exclusion criterion for enrollment into the CARDIA study in 1985 (when participant ages
ranged from 18-30), participants who developed CVD between 1985 and VIM sub-study
enrollment in 2000 were not excluded from participating in either the sub-study or as a
FRAM control. When HIV-infected subjects with pre-existing CVD were excluded from the
analysis, median FRS were essentially unchanged (men 4.8%, women 1.1%), and higher
rates of CVD risk >10% persisted in HIV-infected men compared to controls (p<0.0001).
Additionally, the increased level of risk by FRS was not merely due to the higher prevalence
of smoking in HIV-infected participants. Among non-smokers, the median FRS score was
2.8% (IQR: 1.1-5.3) in HIV-infected and 1.9 (0.9-3.6) in control participants (p = 0.0012),
and the prevalence of FRS > 10% was 7% and 2% (p=0.0063).
Associations of adipose tissue volumes with Framingham risk score
In control men, statistically significant positive correlations were seen between FRS and
percent AT, VAT, and total SAT (p<0.0001), as well as with individual fat depots (Table 3).
FRS showed weaker but still positive associations with AT in control women, with a
statistically significant association seen only for VAT (r=0.26, p=0.0035).
In contrast, percent AT and total SAT showed little association with FRS in HIV-infected
men and women (Table 3), while VAT showed a strong positive association with FRS in
both HIV-infected men and women (r=0.34, p<0.0001). Upper trunk SAT was associated
with FRS in HIV-infected women (r=0.16, p=0.049), with a similar trend in control women.
The association between upper trunk SAT and FRS in HIV-infected men was much weaker
than in control men, and did not reach statistical significance. Most notably, a negative
association of leg SAT with FRS was observed in HIV-infected men (r=−0.13, p=0.015), a
reversal of the relationship seen in controls (r=+0.30, p=0.0003). A weak negative
association with leg SAT was also seen in HIV-infected women.
AT depot associations with FRS were weaker in HIV-infected men compared with control
men (p≤0.0007, by tests for HIV-by-AT depot interactions in all depots). These associations
also appeared to be weaker in HIV-infected women compared with control women, although
the differences did not reach statistical significance. An exception was seen for VAT, with
statistically significant associations with FRS seen in both HIV-infected (r=0.34, p<.0001)
and control women (r=0.26, p=0.0035).
Lipoatrophy and Framingham risk score
We examined the association of VAT and leg SAT with FRS. Figures 1a and 1b show the
median FRS by quartile of VAT and leg SAT. Quartiles were created using cutoffs from the
control group (performed separately for men and women) to facilitate comparison of similar
quantities of AT between HIV-infected and control subjects. A linear relationship was seen
between FRS and VAT in controls, with the lowest FRS values seen in subjects with the
smallest VAT volumes (1st quartile). FRS were highest in participants with the largest VAT
volumes (4th quartile) in both HIV-infected (median 4.6%) and control subjects [median
3.4%, HIV vs. control (men and women combined) p=0.055, Figure 1a]. However, FRS
were higher at every level of VAT in HIV-infected subjects compared to controls, with the
most striking difference in the first VAT quartile (first quartile: 3.4% vs. 1.3%, p<0.0001;
second quartile: 2.8% vs. 2.1%, p=0.021; third quartile: 4.0% vs. 2.7%, p=0.051).
Because leg SAT, a depot strongly affected by HIV-associated lipoatrophy (Saint-Marc et
al., 2000), showed a negative association with FRS in HIV-infected but not control subjects,
we examined this association further. In controls, FRS were lowest in the first (i.e., lowest)
quartile of leg SAT (median 1.6%), and higher in those with greater amounts of leg SAT
(medians 2.4-3.0%). In contrast, median FRS were highest in HIV-infected subjects with the
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smallest quantity of leg SAT (median 4.1%). Within the lowest quartile of leg SAT, FRS in
HIV-infected subjects were significantly higher than in controls (p<0.0001). There was little
difference in median FRS between HIV-infected and control participants in the upper three
quartiles of leg SAT.
We then modeled the association of quartiled VAT and leg SAT with FRS while
simultaneously controlling for both AT depots (Table 4). The overall association of VAT
volume with FRS was stronger in controls than in HIV-infected participants (p=0.0080). In
controls, each quartile of VAT was associated with progressively higher FRS, with
differences between quartiles reaching statistical significance for VAT Q3 (97% higher FRS
compared with Q1, p=0.0018) and Q4 (163% higher vs. Q1, p<0.0001). In HIV-infected
participants, being in the highest quartile (Q4) was associated with 44% higher FRS
compared with being in the lowest quartile (p=0.0090).
The association of leg SAT with FRS was found to have qualitatively different associations
in HIV-infected and control subjects after adjusting for VAT (p=0.0008). In controls, there
was a suggestion of higher FRS for those in the second quartile (41% higher vs. Q1,
p=0.10), but the overall association was flatter in the higher quartiles. By contrast, HIV-
infected participants with leg SAT in the second, third, and fourth quartiles had lower FRS
relative to those with leg SAT in the lowest (1st) quartile.
Discussion and conclusions
In our cohort, 10-year FRS were higher among HIV-infected men than control men, whereas
HIV-infected and control women had similar and low CVD risk scores. The percentage of
HIV-infected men with 10-year FRS >10% was four-fold higher than controls, and may be
partially driven by the higher rates of smoking and lower HDL values in HIV-infected
compared to control men.
Our study is the first to show an independent association of specific, regional, AT depots
with 10-year CVD risk. Our novel finding of associations between AT depots and FRS
suggests AT aberrations may mediate CVD risk in the setting of HIV infection. Increased
VAT and lower leg SAT were associated with higher FRS in both HIV-infected men and
women in our cohort, with some differences seen between the sexes. HIV-infected men
tended to have less VAT and SAT than controls, whereas HIV-infected women had more
VAT and upper trunk SAT than controls. Because increased VAT is known to be associated
with a pro-atherogenic lipid profile (Nieves et al., 2003) and was associated with lower HDL
and elevated triglycerides in HIV-infected and control FRAM participants (J. Currier et al.,
2008; Wohl et al., 2008), the association of VAT with increased FRS was not unexpected.
In contrast, while SAT depots were positively correlated with FRS in controls, a striking
finding in our HIV-infected participants was the negative correlation of leg SAT with FRS,
an association that was stronger in men than women. This negative correlation was driven
by an increase in FRS among those with the lowest leg SAT volumes, reflecting the severity
of lipoatrophy in these subjects (Bacchetti et al., 2005; Fat distribution in women with HIV
infection,” 2006; Kosmiski et al., 2008). Nearly 50% of HIV-infected men and one-third of
HIV-infected women had leg SAT volumes in the lowest decile of leg SAT for controls
(Kosmiski et al., 2008), and, while leg SAT is known to be the most common site of fat loss
in HIV-infected men and women (Bacchetti et al., 2005; Fat distribution in women with
HIV infection,” 2006; Tien et al., 2003), the high prevalence of severe lipoatrophy in our
HIV-infected cohort was surprising. Lower leg SAT has been shown to be associated with
elevated triglyceride levels in both HIV-infected men and women (J. Currier et al., 2008;
Wohl et al., 2008), and associations between lipoatrophy and other CVD risk factors have
been suggested. However, an independent association of specific, regional AT depots with
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10-year CVD risk has not previously been shown. Yim et al recently found femoral-gluteal
SAT to be inversely associated with insulin and TG, but the associations weakened after
controlling for VAT (Yim, Heshka, Albu, Heymsfield, & Gallagher, 2008). What is
particularly novel in our cohort is the association of decreased leg SAT with higher CVD
risk in HIV-infected participants that persisted after controlling for VAT.
It is currently unknown whether the excess risk of HIV-associated atherosclerosis varies by
sex. However, there is growing evidence that women with HIV may experience more excess
cardiovascular events than men with HIV. Triant and colleagues reported higher rates of
acute myocardial infarction in HIV-infected women compared to control women, but similar
rates in HIV-infected and control men after controlling for risk factors other than sex (Triant
et al., 2007). In addition, recent data from FRAM2 (a follow-up evaluation of the original
FRAM participants) suggests that while men had greater absolute carotid intima-medial
thickness (cIMT) than women, the magnitude of positive association between HIV infection
and cIMT was greater for women than men (Grunfeld et al., 2009).
In the age range we examined, FRS did not appear to be increased for HIV-infected women
vs. controls, and the 10-year risk for both groups was low. The Women’s Interagency HIV
Study (WIHS) also observed similar predicted CVD risk between HIV-infected and control
women, and the predicted CVD risk in HIV-infected men from the Multicenter AIDS
Cohort Study (MACS) appeared higher than for control men, although in both studies the
10-year predicted CVD risk was greater than observed in the FRAM study (Kaplan et al.,
2007). Long-term, longitudinal follow-up is necessary to assess whether HIV-infected
women will experience cardiovascular events at a rate greater than predicted by the current
FRS estimates, but is beyond the scope of this cross-sectional analysis and would require a
much larger numbers of subjects. However, given the data above, it is possible that leg SAT
atrophy may contribute more to CVD risk in HIV-infected men with this abnormality,
whereas increased VAT and upper trunk SAT volumes may be the predominant AT changes
associated with CVD risk in HIV-infected women.
Given the excess CVD risk seen in men with HIV and the growing body of data suggesting
heightened risk in women with HIV, a strong argument exists for early cardiovascular
screening and intervention in HIV-infected patients, including those patients with lower FRS
scores. Identifying sex differences in cardiovascular risk should be part of a comprehensive
effort to improve risk identification, develop novel risk stratification tools, and individualize
intervention strategies in HIV-infected men and women.
Limitations of our study include its cross-sectional design, and therefore our ability to
provide evidence of an association between regional AT depot trends and CVD events. FRS
has not been used to predict events in an HIV-infected population; however, it still has merit
both in its provision of a relative estimate of risk, and in its association with site-specific AT
volume, as we have shown here.
As previously reported (Bacchetti et al., 2005; J. Currier et al., 2008; Fat distribution in
women with HIV infection,” 2006; Tien et al., 2006; Wohl et al., 2008), most FRAM
participants were ART-experienced (on ART at the time of exam: men 81%, women 71%;
on ART ever: 92% men, 85% women), and our study was not designed to discern the effects
of long-term or past exposure on current risk. Differences in CVD risk factors between HIV-
infected subjects and controls is another limitation of this study, as minimizing differences
between the groups is critical to accurately assessing the contribution of HIV-specific
covariates. In our cohort, the higher prevalence of smoking in HIV-infected participants
contributed to differences seen in FRS.
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Despite these limitations, we have quantitatively demonstrated associations between
regional AT depots and 10-year FRS amongst participants in the FRAM study. The risk
differences described varied notably between HIV-infected participants and controls, and
within HIV-infected subjects when stratified by sex. Future studies are needed to further our
understanding of these associations, including those addressing sex-specific differences in
the relationship between regional fat deposition and cardiovascular risk.
In HIV-infected subjects, increased VAT, upper trunk SAT, and decreased leg SAT are
associated with 10-year CVD risk. Particularly striking is the negative association of leg
SAT with FRS seen in HIV-infected subjects but not controls, and the degree to which CVD
risk score correlated with severity of lipoatrophy. HIV-infected men had significantly higher
FRS than age-matched controls, while women had similarly-low scores irrespective of HIV
status. Our findings suggest that AT depot abnormalities may independently contribute to
CVD risk in HIV-infected subjects, an observation that warrants further study. Heightened
screening for CVD in patients with lipoatrophy and/or visceral fat accumulation should be
considered to help prevent cardiovascular events for both HIV-infected men and women.
Acknowledgments
The authors thank the study subjects for their generous participation in these investigations.
Financial support: Research support provided by UNC Center for AIDS Research AI050410(-11) and UNC
General Clinical Research Center M01 RR000046-48. FRAM is funded by and performed in cooperation with
NIDDK, NHLBI, NIAID, NIDA & OAR, of the NIH, U.S.A. (R01- DK57508, HL74814, and HL53359; K23
AI66943; JSC K24 AI56933; and NIH center grants M01- RR00036, RR00051, RR00052, RR00054, RR00083,
RR0636, RR00865, and UL1 RR024131), and the Albert L. and Janet A. Schultz Supporting Foundation; and with
resources and the use of facilities of the Veterans Affairs Medical Centers of Atlanta, District of Columbia, New
York, and San Francisco. The funding agencies had no role in the collection or analysis of the data.
References
Aboud M, Elgalib A, Pomeroy L, Panayiotakopoulos G, Skopelitis E, Kulasegaram R, et al.
Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for
clinical management: the CREATE 1 study. Int J Clin Pract. 64(9):1252–1259. [PubMed:
20653801]
Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for
health professionals. Circulation. 1991; 83(1):356–362. [PubMed: 1984895]
Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, et al. Fat distribution
in men with HIV infection. J Acquir Immune Defic Syndr. 2005; 40(2):121–131. [PubMed:
16186728]
Currier J, Scherzer R, Bacchetti P, Heymsfield S, Lee D, Sidney S, et al. Regional adipose tissue and
lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr. 2008; 48(1):35–
43. [PubMed: 18197118]
Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-
infected individuals. J Acquir Immune Defic Syndr. 2003; 33(4):506–512. [PubMed: 12869840]
De Socio GV, Parruti G, Quirino T, Ricci E, Schillaci G, Adriani B, et al. Identifying HIV patients
with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE
study. J Infect. 2008; 57(1):33–40. [PubMed: 18436307]
Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, Lees RS, et al. Increased cardiovascular
disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005; 39(1):44–54.
[PubMed: 15851913]
El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, et al. Effects of HIV
disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV
Med. 2005; 6(2):114–121. [PubMed: 15807717]
Lake et al. Page 8













Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006; 42(5):562–571.
[PubMed: 16837863]
Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr. et al. CARDIA: study
design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;
41(11):1105–1116. [PubMed: 3204420]
Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination
antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349(21):1993–
2003. [PubMed: 14627784]
Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of
cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-
HIV Drugs Study. Eur J Cardiovasc Prev Rehabil.
Gallagher D, Belmonte D, Deurenberg P, Wang Z, Krasnow N, Pi-Sunyer FX, et al. Organ-tissue mass
measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol. 1998;
275(2 Pt 1):E249–258. [PubMed: 9688626]
Galli M, Veglia F, Angarano G, Santambrogio S, Meneghini E, Gritti F, et al. Gender differences in
antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and
develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr. 2003; 34(1):58–61.
[PubMed: 14501794]
Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis
due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS.
2009; 23(14):1841–1849. [PubMed: 19455012]
Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the
acquired immunodeficiency syndrome. Am J Med. 1989; 86(1):27–31. [PubMed: 2910092]
Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins,
triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired
immunodeficiency syndrome. J Clin Endocrinol Metab. 1992; 74(5):1045–1052. [PubMed:
1373735]
Grunfeld C, Rimland D, Gibert CL, Powderly WG, Sidney S, Shlipak MG, et al. Association of upper
trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected
subjects in the FRAM study. J Acquir Immune Defic Syndr. 2007; 46(3):283–290. [PubMed:
18167644]
Hadigan C, Meigs JB, Wilson PW, D’Agostino RB, Davis B, Basgoz N, et al. Prediction of coronary
heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis. 2003; 36(7):
909–916. [PubMed: 12652392]
Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary
heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007; 45(8):1074–1081.
[PubMed: 17879928]
Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, et al. Relationship of
fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol
Metab. 2008; 93(1):216–224. [PubMed: 17940113]
Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in
HIV-infected patients. J Acquir Immune Defic Syndr. 2008; 49(Suppl 2):S79–85. [PubMed:
18725816]
Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, et al. The metabolic effects of
lopinavir/ritonavir in HIV-negative men. AIDS. 2004; 18(4):641–649. [PubMed: 15090769]
Mulligan K, Parker RA, Komarow L, Grinspoon SK, Tebas P, Robbins GK, et al. Mixed patterns of
changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized
trial. J Acquir Immune Defic Syndr. 2006; 41(5):590–597. [PubMed: 16652032]
Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, et al. The atherogenic
lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-
abdominal fat. Diabetes. 2003; 52(1):172–179. [PubMed: 12502509]
Rossi R, Nuzzo A, Guaraldi G, Orlando G, Squillace N, Ligabue G, et al. The role of the Framingham
risk score to predict the presence of subclinical coronary atherosclerosis in patients with HIV
infection. J Acquir Immune Defic Syndr. 2009; 52(2):303–304. [PubMed: 20118681]
Lake et al. Page 9













Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution
evaluated by computed tomography and metabolic abnormalities in patients undergoing
antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000; 14(1):37–49.
[PubMed: 10714566]
Snijder MB, Visser M, Dekker JM, Goodpaster BH, Harris TB, Kritchevsky SB, et al. Low
subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of
high abdominal fat. The Health ABC Study. Diabetologia. 2005; 48(2):301–308. [PubMed:
15660262]
Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human
immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes
and endothelial dysfunction. Circulation. 2001; 104(3):257–262. [PubMed: 11457741]
Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and
metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J
Epidemiol. 2006; 163(9):860–869. [PubMed: 16524955]
Tien PC, Cole SR, Williams CM, Li R, Justman JE, Cohen MH, et al. Incidence of lipoatrophy and
lipohypertrophy in the women’s interagency HIV study. J Acquir Immune Defic Syndr. 2003;
34(5):461–466. [PubMed: 14657755]
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and
cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin
Endocrinol Metab. 2007; 92(7):2506–2512. [PubMed: 17456578]
Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, et al. The associations of
regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune
Defic Syndr. 2008; 48(1):44–52. [PubMed: 18360291]
Yim JE, Heshka S, Albu JB, Heymsfield S, Gallagher D. Femoral-gluteal subcutaneous and
intermuscular adipose tissues have independent and opposing relationships with CVD risk. J Appl
Physiol. 2008; 104(3):700–707. [PubMed: 18079271]
Lake et al. Page 10














Framingham risk score levels by (A) VAT and (B) leg SAT quartile in HIV-infected and
control subjects (Quartile 1=lowest AT volumes)
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Table 4









 Q2 vs. Q1 35.8 (−9.0, 102.5), p=0.13 −0.9 (−25.3, 31.4), p=0.95
 Q3 vs. Q1 97.3 (29.2, 201.2), p=0.0018 23.6 (−6.0, 62.4), p=0.13
 Q4 vs. Q1 163.4 (68.6, 311.5), p<.0001 43.6 (9.5, 88.2), p=0.0090
Leg SAT p=0.0008
 Q2 vs. Q1 40.7 (−6.4, 111.3), p=0.10 −36.8 (−52.8, −15.4), p=0.0021
 Q3 vs. Q1 14.5 (−24.3, 73.2), p=0.52 −34.1 (−52.4, −8.7), p=0.012
 Q4 vs. Q1 −2.2 (−37.5, 53.2), p=0.92 −29.8 (−48.3, −4.7), p=0.023
Note: analysis is age-restricted. FRS is log transformed; results are back transformed to produce percentage estimates.
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